D3-GHR Polymorphism and Turner Syndrome

Completed

• Conditions: Turner Syndrome; Short Stature

• Registration Number: NCT00443144
• Lead Sponsor: University Hospital Tuebingen

Brief Summary

The protein polymorphism of the growth hormone receptor characterized by the genomic deletion of exon 3 has been linked to the magnitude of the first-year-growth response to growth hormone (GH) in girls with Turner syndrome.

Objective: to study the long-term effect of GH therapy in Turner syndrome in correlation to this GHR polymorphism in a mainly retrospective design (chart-review).

Detailed Description

Not available

Study Timeline

• Study Start: 2005-05
• Study First Submitted: 2007-03-02
• Study First Submitted QC: 2007-03-02
• Study First Posted: 2007-03-05
• Primary Completion: 2007-04
• Study Completion: 2007-05
• Status Verified: 2015-12
• Last Update Submitted: 2015-12-02
• Last Update Posted: 2015-12-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

• Turner syndrome defined by a structural aberration or lack of the X chromosome.
• Growth velocity less than 2 cm/year at the time of final analysis (= final height).

Exclusion Criteria

• Age <3.5 or >14 years at start of GH therapy,
• GH peak serum levels < 8 ng/ml in two independent tests,
• Thelarche at start or during the first year of treatment,
• Oxandrolone therapy for any time and a duration of GH therapy less than 2 years.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

University-Children's Hospital; 🇩🇪 Tübingen, Germany